EV/EBITDA Multiple: Agios Pharmaceuticals Inc (AGIO)
The historical EV/EBITDA level for Agios Pharmaceuticals (AGIO) based on the GURU.Markets chart remains around 0.00. The niche market for orphan diseases and regulatory pressure on therapy costs create certain risks. The business model is based on high pricing for rare drugs with minimal production costs, while dependence on a single approved product slows the path to profitability.
agios.com (AGIO) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Agios Pharmaceuticals|AGIO - Long-Term Debt to Equity|Short-Term Debt to Equity Agios Pharmaceuticals, Inc.|AGIO - Company Cumulative Debt|Debt to Book Capitalization Ratio Agios Corp|AGIO - Company Long-Term Debt|Company Short-Term Debts Agios Pharmaceuticals|Quick Liquidity agios.com
- net income and valuation multiples indicators:
AGIO - Net Financial Result|Expected Profit Agios Pharmaceuticals|AGIO - Price to Earnings Ratio|Forward P/E Multiple Agios Pharmaceuticals|AGIO - PEG Multiple|EV/EBITDA Multiple Agios Corp|AGIO - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Agios Pharmaceuticals|AGIO - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months agios.com|AGIO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Agios Pharmaceuticals
Initial company analysis:AGIO (Agios Pharmaceuticals Inc)
This ratio compares the total value of assets and liabilities with operating income before depreciation and amortization, allowing for an assessment of the business's real value regardless of tax policy and debt structure. In the case of Agios Pharmaceuticals (AGIO), this calculation is critical for analyzing capital intensity during the implementation of orphan drugs, which clearly reflects the change in the EV/EBITDA multiple within the context of cash reserve stability.
Who Agios Pharmaceuticals competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|EV/EBITDA Multiple BIOA (BioAge Labs, Inc.)|EV/EBITDA Multiple biomeafusion.com BMEA|Quince - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Fractyl Health Inc. (GUTS)|VTVT: EV/EBITDA Multiple|ATPC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pluristem Therapeutics|Company Value to EBITDA Synlogic Corp SYBX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipocine (LPCN)|Total Company Value to Operating Income Before Depreciation Ratio matinasbiopharma.com|Spruce Biosciences - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GLTO|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|ONVO: EV/EBITDA Multiple|Radius Recycling Inc. - Business Value to Operating Income Before Depreciation
